

#### FINAL STUDY REPORT

# STUDY TITLE

Evaluation of Antiviral Properties of a Product Using a Virucidal Suspension Assay

Virus: Coxsackievirus type A16

# **PRODUCT IDENTITY**

The Germ Killer
Lot BN100296 and Lot BNL100001

## **AUTHOR**

Shanen Conway, B.S. Study Director

# STUDY COMPLETION DATE

March 2, 2011

# PERFORMING LABORATORY

ATS Labs 1285 Corporate Center Drive, Suite 110 Eagan, MN 55121

# **SPONSOR**

Vance Chemicals Pte. Ltd. No. 24 Gul Lane Singapore 629418

# PROJECT NUMBER

A10971

Page 1 of 23



#### STUDY REPORT

#### **GENERAL STUDY INFORMATION**

Study Title: Evaluation of Antiviral Properties of a Product Using a Virucidal Suspension

Assay

Project Number: A10971

Protocol Number: VBS01020711.COX

Sponsor: Vance Chemicals Pte. Ltd.

No. 24 Gul Lane Singapore 629418

Testing Facility: ATS Labs

1285 Corporate Center Drive, Suite 110

Eagan, MN 55121

### **TEST SUBSTANCE IDENTITY**

Test Substance: The Germ Killer

Lot/Batch(s): BN100296 and BNL100001

# **Test Substance Characterization**

Test substance characterization as to content, stability, solubility, storage, etc., (21 CFR, Part 58, Subpart F [58.105]) is the responsibility of the Sponsor.

#### STUDY DATES

Date Sample Received: July 14, 2010 (Lot BN100296) July 15, 2010 (Lot BNL100001)

Study Initiation Date: February 15, 2011
Experimental Start Date: February 16, 2011
Experimental End Date: February 23, 2011
Study Completion Date: March 2, 2011

# **OBJECTIVE**

The objective of this study was to evaluate the antiviral properties of a product against Coxsackievirus type A16 when exposed (in suspension) for a specified exposure period(s). The protocol is a modification of the Standard Test Method for Efficacy of Antimicrobial Agents Against Viruses in Suspension (ASTM E 1052).

ATS: LA Page 7 of 23

#### **SUMMARY OF RESULTS**

Test Substance:

The Germ Killer, Lot BN100296 and Lot BNL100001

Dilution Tested:

Ready to use (RTU)

Virus:

Coxsackievirus type A16, Strain G10, ATCC VR-174

Exposure Time:

5 minutes

Exposure Temperature:

Room temperature (20.0°C)

Organic Soil Load:

1% fetal bovine serum

Efficacy Result:

Under these test conditions, The Germ Killer (BN100296) demonstrated a 90% reduction in the stock virus titer as compared to the titer of the corresponding virus control. The Germ Killer (BNL100001) demonstrated a 98.2% reduction in the stock virus titer as compared to the titer of the corresponding virus control. The log reductions in viral titer were 1.0 log<sub>10</sub>

and 1.75 log<sub>10</sub>, respectively.

# TEST SYSTEM

#### 1. Virus

The G10 strain of Coxsackievirus type A16 used for this study was obtained from the American Type Culture Collection, Manassas, VA (ATCC VR-174). Stock virus was prepared by collecting the supernatant culture fluid from 75-100% infected culture cells. The cells were disrupted and cell debris removed by centrifugation at approximately 2000 RPM for five minutes at approximately 4°C. The supernatant was removed, aliquoted, and the high titer stock virus was stored at ≤-70°C until the day of use. On the day of use an aliquot of stock virus (ATS Labs Lot CX16-36) was removed, thawed and maintained at a refrigerated temperature until used in the assay. The stock virus culture was adjusted to contain 1% fetal bovine serum as the organic soil load. The stock virus tested demonstrated cytopathic effects (CPE) typical of Coxsackievirus on LLC-MK2 (Rhesus monkey kidney) cells.

#### 2. Indicator Cell Cultures

LLC-MK<sub>2</sub> (Rhesus monkey kidney) cells were originally obtained from the American Type Culture Collection, Manassas, VA (ATCC CCL-7.1). The cells were propagated by ATS Labs personnel. The cells were seeded into multiwell cell culture plates and maintained at 36-38°C in a humidified atmosphere of 5-7% CO2. On the day of testing, cells were observed as having proper cell integrity and confluency, and therefore, were acceptable for use in this study. On the day of testing, cells were observed as having proper cell integrity and confluency and therefore, were acceptable for use in this study.

All cell culture documentation was retained for the cell cultures used in the assay with respect to source, passage number, growth characteristics, seeding densities and the general condition of the cells.

### STUDY RESULTS

## Cytotoxicity and Neutralization Controls

Test substance cytotoxicity was observed at 3.5  $\log_{10}$ . The neutralization control demonstrated that the test substance was neutralized at  $\leq$ 3.5  $\log_{10}$ .

## 5 Minute Exposure Time

The titer of the virus control was  $5.5 \log_{10}$ . Following exposure, test virus infectivity was detected in the virus-test substance mixture at  $4.5 \log_{10}$  for Lot BN100296 and  $3.75 \log_{10}$  for Lot BNL100001. Lot BN100296 demonstrated a log reduction of  $1.0 \log_{10}$ . Lot BNL100001 demonstrated a log reduction of  $1.75 \log_{10}$ .

## STUDY CONCLUSION

Under the conditions of this investigation, in the presence of a 1% fetal bovine serum organic soil load, The Germ Killer (Lot BN100296), ready to use, demonstrated a 90.0% reduction in viral titer following a 5 minute exposure time to Coxsackievirus type A16 as compared to the titer of the corresponding virus control. Lot BN100296 demonstrated a log reduction of  $1.0 \log_{10}$ .

Under the conditions of this investigation, in the presence of a 1% fetal bovine serum organic soil load, The Germ Killer (Lot BNL100001), ready to use, demonstrated a 98.2% reduction in viral titer following a 5 minute exposure time to Coxsackievirus type A16 as compared to the titer of the corresponding virus control. Lot BNL100001 demonstrated a log reduction of 1.75 log<sub>10</sub>.

In the opinion of the Study Director, there were no circumstances that may have adversely affected the quality or integrity of the data.

The use of the ATS Labs name, logo or any other representation of ATS Labs without the written approval of ATS Labs is prohibited. In addition, ATS Labs may not be referred to in any form of promotional materials, press releases, advertising or similar materials (whether by print, broadcast, communication or electronic means) without the express written permission of ATS Labs.